On November 2, 2026, Fresenius announced that it had entered into an exclusive development agreement with WuXi Biologics for the research, development, and manufacturing of biosimilars. The agreement provides Fresenius with exclusive access to up to 37 identified biosimilar candidates spanning 13 therapeutic areas, including neurology, nephrology, cardiopulmonary, oncology, immunology,…
